Frequent Loss of Claudin-4 Expression in Dedifferentiated and Undifferentiated Endometrial Carcinomas

Overview

Journal Histopathology

Specialties Anatomy & Histology
Pathology

Date 2018 Apr 20

PMID 29671892

Citations 9

Authors

Basile Tessier-Cloutier

Robert A Soslow

Colin J R Stewart

Martin Kobel

Cheng-Han Lee

Affiliations

Soon will be listed here.

Abstract

Aims: Dedifferentiated endometrial carcinomas (DDECs)/undifferentiated endometrial carcinomas (UECs) are aggressive endometrial cancers with frequent genomic inactivation of core components of switch/sucrose non-fermentable (SWI/SNF) complex proteins. Claudin-4, an epithelial intercellular tight junction protein, was recently found to be expressed in SWI/SNF-deficient undifferentiated carcinomas but not in SWI/SNF-deficient sarcomas. The aim of this study was to examine claudin-4 expression in UECs/DDECs and other high-grade uterine carcinomas.

Methods And Results: We examined claudin-4 expression by immunohistochemistry (clone 3E2C1) on tissue microarrays that contained 44 UECs/DDECs (24 SWI/SNF-deficient), 50 carcinosarcomas, 164 grade 3 endometrioid carcinomas, 57 serous carcinomas, and 20 clear cell carcinomas. Tumours with <5% claudin-4 expression were considered to be negative. Nearly all SWI/SNF-deficient, and most SWI/SNF-proficient, UECs/DDECs showed a complete absence of claudin-4 expression in the undifferentiated component, whereas the differentiated component in DDECs showed consistent and diffuse claudin-4 expression. Only one SWI/SNF-deficient DDEC showed focal expression of claudin-4 in the undifferentiated component, as compared with diffuse expression in the corresponding differentiated component. Claudin-4 expression was consistently absent in the sarcomatous component of carcinosarcoma, and it was absent in 24% of grade 3 endometrioid carcinomas and serous carcinomas.

Conclusion: Claudin-4 expression can be absent or very focal in a subset of high-grade endometrial carcinomas, and is almost always absent in the undifferentiated components of SWI/SNF-deficient UECs/DDECs, despite the apparent epithelial origin in the case of DDECs. Therefore, claudin-4 expression cannot be used to infer mesenchymal or epithelial tumour origin in the endometrium. The consistent loss or down-regulation of claudin-4, a tight junction protein, in SWI/SNF-deficient UECs/DDECs further supports the undifferentiated nature of these tumours.

Citing Articles

Claudins in Cancer: A Current and Future Therapeutic Target.

Hana C, Thaw Dar N, Galo Venegas M, Vulfovich M Int J Mol Sci. 2024; 25(9).

PMID: 38731853 PMC: 11083183. DOI: 10.3390/ijms25094634.

The Roles of Tricellular Tight Junction Protein Angulin-1/Lipolysis-Stimulated Lipoprotein Receptor (LSR) in Endometriosis and Endometrioid-Endometrial Carcinoma.

Shimada H, Kohno T, Konno T, Okada T, Saito K, Shindo Y Cancers (Basel). 2021; 13(24).

PMID: 34944960 PMC: 8699113. DOI: 10.3390/cancers13246341.

Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.

Orlando K, Douglas A, Abudu A, Wang Y, Tessier-Cloutier B, Su W Elife. 2020; 9.

PMID: 33355532 PMC: 7813545. DOI: 10.7554/eLife.59073.

Claudins: New Players in Human Fertility and Reproductive System Cancers.

Koziel M, Kowalska K, Piastowska-Ciesielska A Cancers (Basel). 2020; 12(3).

PMID: 32197343 PMC: 7140004. DOI: 10.3390/cancers12030711.

SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.

Wang Y, Hoang L, Ji J, Huntsman D Annu Rev Pathol. 2020; 15:467-492.

PMID: 31977292 PMC: 6986318. DOI: 10.1146/annurev-pathmechdis-012418-012917.

References

Van Itallie C, Rahner C, Anderson J . Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J Clin Invest. 2001; 107(10):1319-27. PMC: 209303. DOI: 10.1172/JCI12464. View

Altrabulsi B, Malpica A, Deavers M, Bodurka D, Broaddus R, Silva E . Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005; 29(10):1316-21. DOI: 10.1097/01.pas.0000171003.72352.9a. View

Pan X, Wang B, Che Y, Weng Z, Dai H, Peng W . Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gynecol Cancer. 2007; 17(1):233-41. DOI: 10.1111/j.1525-1438.2006.00748.x. View

Lanigan F, McKiernan E, Brennan D, Hegarty S, Millikan R, McBryan J . Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer. 2009; 124(9):2088-97. DOI: 10.1002/ijc.24159. View

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith W, Fedorov O . Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-73. PMC: 3010259. DOI: 10.1038/nature09504. View

Beeman N, Webb P, Baumgartner H . Occludin is required for apoptosis when claudin-claudin interactions are disrupted. Cell Death Dis. 2012; 3:e273. PMC: 3288343. DOI: 10.1038/cddis.2012.14. View

Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick M . Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol. 2012; 26(4):485-95. PMC: 4000969. DOI: 10.1038/modpathol.2012.187. View

Holczbauer A, Gyongyosi B, Lotz G, Szijarto A, Kupcsulik P, Schaff Z . Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas. J Histochem Cytochem. 2013; 61(4):294-305. PMC: 3636686. DOI: 10.1369/0022155413479123. View

Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K . A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 2013; 73(17):5508-18. DOI: 10.1158/0008-5472.CAN-12-4593. View

10.

Ding L, Lu Z, Lu Q, Chen Y . The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res. 2013; 5:367-75. PMC: 3825674. DOI: 10.2147/CMAR.S38294. View

11.

Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih I . Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol. 2014; 38(5):660-5. DOI: 10.1097/PAS.0000000000000166. View

12.

Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter D . SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol. 2014; 38(9):1274-81. PMC: 4141899. DOI: 10.1097/PAS.0000000000000236. View

13.

Hoang L, Ali R, Lau S, Gilks C, Lee C . Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol. 2014; 33(5):483-91. DOI: 10.1097/PGP.0b013e31829ff239. View

14.

Hwang T, Changchien T, Wang C, Wu C . Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncol Lett. 2014; 8(3):1367-1371. PMC: 4114660. DOI: 10.3892/ol.2014.2295. View

15.

Helming K, Wang X, Roberts C . Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 2014; 26(3):309-317. PMC: 4159614. DOI: 10.1016/j.ccr.2014.07.018. View

16.

Ma X, Miao H, Jing B, Pan Q, Zhang H, Chen Y . Claudin-4 controls the proliferation, apoptosis, migration and in vivo growth of MCF-7 breast cancer cells. Oncol Rep. 2015; 34(2):681-90. DOI: 10.3892/or.2015.4037. View

17.

Liu J, Wei Z, Chen J, Lu H, Hao L, Li W . Prognostic and clinical significance of claudin-4 in gastric cancer: a meta-analysis. World J Surg Oncol. 2015; 13:207. PMC: 4481068. DOI: 10.1186/s12957-015-0626-2. View

18.

Karnezis A, Hoang L, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B . Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016; 29(3):302-14. PMC: 4980656. DOI: 10.1038/modpathol.2015.155. View

19.

Hoang L, Lee Y, Karnezis A, Tessier-Cloutier B, Almandani N, Coatham M . Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours. Histopathology. 2016; 69(4):560-9. PMC: 5516928. DOI: 10.1111/his.12989. View

20.

Coatham M, Li X, Karnezis A, Hoang L, Tessier-Cloutier B, Meng B . Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol. 2016; 29(12):1586-1593. DOI: 10.1038/modpathol.2016.156. View